Diabetes and Nerve Disorders

What is Neuropathy?

Neuropathy is a general term for damage or dysfunction of nerves. It can affect sensory, motor, or autonomic nerves and may occur in different parts of the body.

While diabetes is one of the most common causes, neuropathy can also result from a variety of other conditions and factors, including:

  • Chronic alcohol abuse
  • Vitamin deficiencies (especially vitamin B12)
  • Infections (such as shingles or HIV)
  • Autoimmune diseases
  • Kidney or liver disease
  • Exposure to toxins or certain medications (e.g., chemotherapy)
  • Genetic disorders

The symptoms of neuropathy vary depending on the type and cause but may include numbness, tingling, pain, muscle weakness, or problems with internal organ function.

Diabetic Neuropathy

Damage to nerve cells caused by diabetes is called “diabetic neuropathy.” About half of all people with diabetes are affected.

Nerves control many conscious and unconscious processes in our body:

  1. Movement of muscles (motor nerves)
  2. Various sensations (sensory nerves) such as touch and vibration, temperature, and pain, as well as processes beyond conscious control
  3. Vegetative processes (autonomic nerves) such as sweating, digestion, and heartbeat

The symptoms of polyneuropathy depend on which nerves are damaged. Because many different nerves are usually affected, it is referred to as “polyneuropathy.”

It usually begins in the feet and initially leads to abnormal sensations and pain, which worsen at rest and in warmth (e.g., at night in bed). As the damage progresses, the symptoms may disappear; pressure, pain, and heat are no longer felt. If dry skin (due to autonomic damage affecting sweating) and muscle wasting with deformities (due to motor damage) are also present, this is referred to as “diabetic foot syndrome.”

Types of “Polyneuropathy”

1) Sensorimotor polyneuropathy:
This refers to damage to sensory and motor nerve fibers.

Impairment of sensory nerve function manifests as disturbances in sensation (vibration, pressure, perception of warmth/cold, and pain), while impairment of motor nerve function leads to paralysis. The most important examination methods are testing vibration sensitivity with a tuning fork and testing reflexes with a reflex hammer.

2) Autonomic neuropathy:
This refers to damage to the autonomic (involuntary) nervous system, which controls the internal organs.

Signs may include: a persistently elevated heart rate, diarrhea or constipation, bladder emptying disorders, a significant drop in blood pressure upon standing, and erectile dysfunction in men. The diagnostic procedures are complex and are usually carried out by specialists for the respective organs.

Diagnosis of Polyneuropathy

The diagnosis of polyneuropathy is based on a combination of medical history, clinical examination, and additional diagnostic tests.

A detailed patient history focuses on symptoms such as numbness, tingling, pain, gait instability, and autonomic complaints. The clinical examination includes testing of sensory function (vibration, temperature, pain, and pressure), muscle strength, coordination, and reflexes.

The physician first asks about typical symptoms such as numbness, tingling, burning pain, reduced sensitivity to temperature, or a “pins and needles” sensation, especially in the feet. Symptoms often begin symmetrically and progress from the toes upward (“stocking distribution”). Questions about diabetes control, duration of the disease, alcohol use, medications, and other conditions are also important.

Electrophysiological studies, such as nerve conduction studies (NCS) and electromyography (EMG), are important tools to confirm the presence, type, and extent of nerve damage. In selected cases, additional tests such as quantitative sensory testing, autonomic function testing, or skin biopsy (to assess small nerve fibers) may be performed.

Laboratory tests are essential to identify underlying causes. These typically include blood glucose and HbA1c levels, vitamin B12, kidney and liver function, thyroid function, and screening for infections or autoimmune diseases.

Differential diagnosis of diabetic polyneuropathy

Diabetic polyneuropathy is primarily a diagnosis of exclusion. Although a length-dependent, symmetrical, distal sensorimotor neuropathy is typical for diabetes, other causes must be considered, especially if the presentation is atypical.

Features that may suggest alternative or additional causes include:

  • Rapid onset or progression
  • Asymmetrical symptoms
  • Predominantly motor deficits
  • Severe pain early in the course
  • Involvement of upper limbs at an early stage

Important differential diagnoses include alcohol-related neuropathy, vitamin deficiencies (especially B12), toxic neuropathies, chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary neuropathies, and neuropathies associated with systemic diseases.

A careful evaluation of clinical features, laboratory findings, and electrophysiological results is necessary to distinguish diabetic neuropathy from other forms and to identify potentially treatable causes.

Physical and neurological examination
A focused neurological exam evaluates different nerve functions:

  • Vibration sense: Tested using a tuning fork (usually 128 Hz) placed on bony areas of the foot (e.g., the big toe). Reduced or absent vibration perception is an early sign of neuropathy.
  • Pressure perception: Often assessed with a monofilament (e.g., 10 g). The patient indicates whether they can feel light pressure at specific points on the sole. Loss of pressure sensation indicates a higher risk of foot ulcers.
  • Temperature sensation: The ability to distinguish between warm and cold stimuli is tested, as small nerve fibers are responsible for this function.
  • Pain perception: A light pinprick test evaluates whether the patient can feel sharp sensations.
  • Reflexes: The Achilles tendon reflex is commonly reduced or absent in polyneuropathy.
  • Muscle strength and appearance: The doctor checks for weakness, muscle wasting, or deformities of the foot.
  1. Quantitative sensory testing (QST)
    In more specialized settings, standardized methods measure sensory thresholds for vibration, temperature, and pain more precisely. These tests help quantify the degree of nerve impairment.
  2. Nerve conduction studies (electroneurography)
    If the diagnosis is unclear or needs confirmation, nerve conduction velocity (NCV) tests are performed. Electrodes measure how fast and how strongly electrical signals travel along the nerves. Slowed conduction or reduced signal amplitude indicates nerve damage, particularly of large fibers.
  3. Additional tests (if needed)
  • Autonomic function tests: Evaluate sweating, heart rate variability, or blood pressure regulation if autonomic neuropathy is suspected.
  • Skin biopsy or corneal confocal microscopy: In selected cases, these can assess small nerve fiber density.
  • Laboratory tests: Used to exclude other causes of neuropathy (e.g., vitamin deficiencies, thyroid disorders, kidney disease).
  1. Early detection of complications (e.g., Charcot foot)
    Since conditions like Charcot foot may initially present with painless swelling and redness, careful clinical examination is essential. Imaging techniques such as X-rays, MRI, or CT scans may be used if Charcot arthropathy is suspected, especially in early stages when changes are subtle.

Overall, diagnosis is not based on a single test but on a combination of findings. Early and regular screening—especially in people with diabetes—is crucial to prevent complications such as foot ulcers and amputations. 

 

Treatment options

The management of diabetic polyneuropathy focuses on three main goals:

  1. Optimal control of blood glucose
  2. Relief of symptoms (especially pain)
  3. Prevention of complications (e.g., diabetic foot syndrome)

1) Glycemic control

Strict and stable blood glucose control is the cornerstone of treatment. Good glycemic control can prevent or significantly delay the progression of neuropathy and may lead to an improvement in symptoms. This includes lifestyle measures, oral antidiabetic drugs, and/or insulin therapy as appropriate.

2) Pharmacological treatment of neuropathic pain

Neuropathic pain often requires specific medications, as conventional analgesics are usually insufficient.

First-line medications:

  • Duloxetine (a serotonin-norepinephrine reuptake inhibitor):
    Starting dose: 30 mg once daily
    Typical dose: 60 mg once daily (maximum 120 mg/day)
  • Pregabalin (antiepileptic):
    Starting dose: 75 mg twice daily
    Usual dose: 150–300 mg/day (maximum 600 mg/day)
  • Gabapentin (antiepileptic):
    Starting dose: 300 mg once daily
    Titrated up to: 900–3600 mg/day in divided doses
  • Amitriptyline (tricyclic antidepressant):
    Starting dose: 10–25 mg at night
    Typical dose: 25–75 mg/day (sometimes up to 150 mg/day depending on tolerance)

Second-line or adjunct therapies:

  • Tramadol (opioid analgesic):
    50–100 mg every 4–6 hours (maximum 400 mg/day)
  • Tapentadol (opioid with noradrenergic activity):
    Typically 50–250 mg twice daily (extended release)

Opioids should be used cautiously and usually only if first-line therapies are insufficient.

Pathogenetic treatment (targeting nerve damage)

  • Alpha-lipoic acid
    An antioxidant that may improve nerve function in some patients.
    Typical dosing:
    • Intravenous: 600 mg daily for 2–3 weeks

Oral: 600 mg daily for maintenance

3) Topical treatments

  • Capsaicin cream (0.025%–0.075%):
    Applied 3–4 times daily to painful areas. Initial burning sensation is common but often decreases with continued use.
  • High-dose capsaicin patch (8%):
    Applied under medical supervision for 30–60 minutes; effects may last several weeks.
  • Cabbage (Graham’s) wraps with capsaicin effect:
    Traditional applications such as cabbage leaf wraps may provide mild symptomatic relief through cooling, anti-inflammatory, and circulation-enhancing effects. While not a standard medical therapy, they can be used as supportive measures in selected patients.

4) Physical and supportive therapies

Non-pharmacological approaches can complement medication:

  • Warm or cold compresses
  • Alternating baths
  • Kneipp hydrotherapy
  • Physiotherapy to maintain mobility and muscle strength
  • Proper foot care and pressure relief (essential for prevention of ulcers)

5) Transcutaneous Electrical Nerve Stimulation (TENS)

TENS is a non-invasive treatment that uses low-voltage electrical currents to relieve pain.

How it works:
Electrodes are placed on the skin over the painful area. A portable device delivers electrical impulses that stimulate sensory nerves. This may reduce pain through:

  • Activation of inhibitory pathways (“gate control theory”)
  • Increased release of endorphins
  • Modulation of pain signal transmission in the spinal cord

Application:

  • Typically used for 20–30 minutes per session
  • Can be applied several times daily
  • Frequency and intensity are adjusted individually

TENS is generally well tolerated and can be particularly useful in patients who do not achieve sufficient relief with medication alone.

6) Treatment of autonomic complications

Autonomic neuropathy requires targeted therapy depending on the organ involved:

  • Cardiovascular: management of orthostatic hypotension (e.g., fluid intake, compression stockings, medications)
  • Gastrointestinal: treatment of diarrhea or constipation
  • Urogenital: management of bladder dysfunction or erectile dysfunction

These treatments are usually initiated by specialists but require coordination by a general practitioner or diabetologist.

Overall, treatment of diabetic polyneuropathy is individualized and often requires a combination of pharmacological and non-pharmacological approaches to achieve optimal symptom control and prevent complications.

There is no single cure for diabetic polyneuropathy, but a combination approach—tight glucose control, lifestyle changes, symptom-oriented medication, and careful foot care—can significantly slow progression, reduce pain, and prevent serious complications.

 

References

  1. Pop-Busui R, Boulton AJM, Feldman EL, et al.
    Diabetic Neuropathy: A Position Statement by the American Diabetes Association.
    Diabetes Care. 2017;40(1):136–154.
  2. American Diabetes Association
    Standards of Medical Care in Diabetes – 2024.
    Diabetes Care. (Updated annually)
  3. Tesfaye S, Boulton AJM, Dyck PJ, et al.
    Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments.
    Diabetes Care. 2010;33(10):2285–2293.
  4. International Diabetes Federation (IDF)
    Clinical Practice Recommendations for Diabetic Neuropathy.
  5. Bril V, England J, Franklin GM, et al.
    Evidence-based guideline: Treatment of painful diabetic neuropathy.
    Neurology. 2011;76(20):1758–1765.
  6. European Federation of Neurological Societies (EFNS)
    Guidelines on the pharmacological treatment of neuropathic pain.
    European Journal of Neurology.
  7. Finnerup NB, Attal N, Haroutounian S, et al.
    Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.
    Lancet Neurology. 2015;14(2):162–173.
  8. Dworkin RH, O’Connor AB, Backonja M, et al.
    Pharmacologic management of neuropathic pain: Evidence-based recommendations.
    Pain. 2007;132(3):237–251.
  9. Johnson MI, Walsh DM.
    Transcutaneous electrical nerve stimulation (TENS): mechanisms, clinical application and evidence.
    British Journal of Pain. 2010.
  10. Backonja M, Wallace MS, Blonsky ER, et al.
    NGX-4010 (Capsaicin 8% patch) for the treatment of painful diabetic peripheral neuropathy.
    Lancet Neurology. 2008;7(12):1106–1112.